People · Operator
Named in public records as an officer, director or promoter · active 2016–2021 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| X4 Pharmaceuticals, Inc | — | Biotechnology | Series C | $320.3M | $494.8M | 2016 |
| Xilio Therapeutics, Inc. | — | Biotechnology | Series C | $145.2M | $3.0B | 2021 |
Rene Russo at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Rene Russo on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Ross | 2 | 18 |
| Carl Gordon | 1 | 24 |
| DAVID GARDNER | 1 | 20 |
| Robert Weisskoff | 1 | 12 |
| Amy Schulman | 1 | 11 |
| Terrance McGuire | 1 | 9 |
| CARL L. GORDON | 1 | 7 |
| Daniel Lynch | 1 | 7 |
| Michael Gray | 1 | 6 |
| David Grayzel | 1 | 6 |
| Tillman Gerngross | 1 | 5 |
| Andrew Hack | 1 | 5 |
| Tillman U. Gerngross | 1 | 5 |
| Michael Wyzga | 1 | 5 |
| Errik B. Anderson | 1 | 5 |
| Claudio Nessi | 1 | 5 |
| William Aliski | 1 | 4 |
| Daniel Burgess | 1 | 4 |
| Robert L. Birnbaum | 1 | 4 |
| Nancy Hong | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.